A high level of BCAT1 expression was identified in gliomas and leukemia with wild-type IDH, and mimics the mutant IDH phenotype in which aberrant production of 2-hydroxyglutarate competitively inhibits αKG function (47–49). Here, BCAT1 is linked to central nervous system cancer.